Sutimlimab-jome

(Enjaymo)

Sutimlimab-jome

Drug updated on 1/4/2024

Dosage FormInjection (intravenous; 1,100 mg/22 mL (50 mg/mL))
Drug ClassComplement inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD).

Product Monograph / Prescribing Information

Document TitleYearSource
Enjaymo (sutimlimab-jome) Prescribing Information.2022Bioverativ USA Inc., Waltham, MA

Randomized Controlled Trials


Sex Distribution:

F:68%
M:32%
22Subjects

Year:

2023

Source:American Journal of Hematology


Sex Distribution:

F:20%
M:80%
202Subjects

Year:

2023

Source:The journal of pharmacology and experimental therapeutics